格拉尼尔格拉尼尔异oprenoids 和肝脏Rap1a调节基底和他类药物诱导的PCSK9的表达
Yating Wang1, Brea Tinsley2, Stefano Spolitu2
1Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA; Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, China.
Journal of lipid research
|February 3, 2024
概括
格拉尼尔格拉尼尔异oprenoids 和 Rap1a 调节PCSK9水平,影响胆固醇平衡. 阻断Rap1a前化有助于他类药物诱导的PCSK9,揭示了心血管疾病的新治疗点.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 心血管研究研究心血管研究
背景情况:
- 降低LDL-C对于预防动脉样硬化心血管疾病至关重要.
- 抑制9型蛋白转化酶亚素/素 (PCSK9) 有效地降低了LDL-C,并减少了心血管事件.
- 类药物,广泛使用的降胆固醇药物,矛盾地增加PCSK9水平,限制其有效性.
研究的目的:
- 调查杰拉尼尔杰拉尼尔异oprenoids和肝脏Rap1a在调节PCSK9表达中的作用.
- 阐明他类药物诱导PCSK9.9的机制.
- 确定管理胆固醇水平和心血管风险的新型治疗点.
主要方法:
- 研究了基拉尼尔基拉尼尔异oprenoids 和肝脏Rap1a.a. 的PCSK9表达调节.
- 研究了他类药物治疗对肝细胞和小鼠Rap1a活性和PCSK9水平的影响.
- 利用Rap1a的小分子激活剂来评估它们对PCSK9和血胆固醇的影响.
- 分析了下游的信号通路,包括RhoA-ROCK通路.
主要成果:
- 杰拉尼尔杰拉尼尔异oprenoids 和肝脏Rap1a 调节基底和他类药物诱导的PCSK9表达.
- 达丁治疗抑制了Rap1a的前化和活性,导致PCSK9.9的增加.
- 通过他类药物介导的PCSK9诱导依赖于日拉尼尔日拉尼尔合成和肝脏Rap1a.
- 在小鼠中激活Rap1a降低了PCSK9蛋白和血胆固醇,并在肝细胞中抑制了他类药物诱导的PCSK9.
- 该机制涉及RhoA-ROCK通路和PCSK9.9的转录后调节.
结论:
- Rap1a是一种新型调节PCSK9蛋白水平的新型调节剂.
- 通过降低geranylgeranyl水平来抑制Rap1a前化,有助于通过他类药物介导的PCSK9诱导.
- 向Rap1a前化是一种潜在的治疗策略,可以提高他类药物的疗效并控制胆固醇水平.
相关概念视频
Regulation of Nuclear Protein Sorting
2.4K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
Regulation of Expression at Multiple Steps
910
The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
910
Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


